Heart failure arises when the heart’s ability to pump blood around the body is impaired. This deprives the body’s tissues of the oxygen and nutrients upon which their survival depends. It commonly occurs as a result of conditions such as ischaemic heart disease, diabetes and high blood pressure.
Featured Learning Zones
Welcome to the Fluid Management Learning Zone. In this Learning Zone we provide an overview of fluid management, including albumin for sepsis and septic shock, guidelines for fluid management in liver cirrhosis and fluid management in cardiac surgery.
Heart failure may be classified as being either acute or chronic. Acute heart failure is characterised by a sudden onset of symptoms, whereas in chronic heart failure typically develops and worsens over time.
Examples of the symptoms associated with heart failure include dyspnoea, fatigue, difficulty exercising, and oedema, particularly peripheral oedema. Symptoms may vary depending on which side or sides of the heart are affected.
Related news and insights
scPharmaceuticals Inc. announced that on February 19, 2021, the Company received the official Type A meeting minutes from the FDA regarding the requirements for resubmission of the Furoscix 505(b)(2) New Drug Application (NDA) following the Complete Response Letter (CRL) received on December 3, 2020.
The FDA has approved an expanded indication for Entresto (sacubitril/valsartan), from Novartis, to reduce the risk of cardiovascular death and hospitalization for heart failure in adult patients with chronic heart failure. Benefits are most clearly evident in patients with left ventricular ejection fraction (LVEF) below normal.
Boston Scientific is recalling the EMBLEM S-ICD Subcutaneous Electrode because of increased risk of fractures at a specific point (distal to the proximal sense ring) If the device fractures during use, it could become unable to deliver therapy to slow very fast heartbeats from cardiac arrest (tachycardia).
An update of the 2012 systematic review and meta-analyses were performed and a modified-GRADE approach was used to update the recommendation for the use of adaptive servo-ventilation (ASV) for the treatment of central sleep apnea syndrome (CSAS)...